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THE radiotherapy of advanced and inoperable tumours by the internal
administration of organic compounds labelled with radioactive isotopes, has been
a special interest of Mitchell and his co-workers in this department (Marrian,
Marshall and Mitchell, 1961; Mitchell et al., 1963). Tritium has been the
radioactive isotope of choice by reason of the very small mean path length, and
hence the highly localised effect, ofits,1 particle in tissues. The feasibility ofthis
approach depends on having an organic molecule which shows a certain degree of
selective uptake into the malignant cells. During the course of these investiga-
tions we have examined the suitability of mepacrine (6-chloro-9-(4-diethylamino-
l-methylbutylamino)-2-methoxyacridine) as a carrier for the tritium.
Evidence that normal mepacrine shows a limited carcinostatic activity has.
been obtained by several groups (Hartwell et al., 1946; Lewis and Goland, 1948;
Vassey et al., 1955; Radzikowski et al., 1962). Recently Gellhorn and his co-
workers (1961) have shown that anti-tumour effects can be obtained provided that
a sufficiently high concentration of the drug can be introduced into the tumour.
On this basis they have demonstrated mepacrine to be useful clinically for the
control of neoplastic effusions. The mode by which mepacrine exerts this action
remains unknown and it has not been established whether the compound itself or-
a metabolite is the active entity. There have been suggestions however, that this.
effect is associated with a selective concentration ofthe compoundin the malignant
tissue. Thus mepacrine administered to mice bearing a transplanted sarcoma or a.
spontaneousmammarygland carcinomawasreported to lead to a selective staining
of the tumour (Lewis and Goland, 1948). This effect was not confirmed by a,
subsequent quantitative study (Vassey et al., 1955). However, in 44 out of 51
biopsies oftumours from patients treated with mepacrine, the concentration ofthe
compound in the malignant tissue was found to be higher than in what was.
considered to be a normal part of the same organ (Brilmayer et al., 1955). The-
same group also reported that tumour-bearing rats, injected with mepacrine,
showed an overall selective uptake in the tumour after 48 hours. In rabbits,
however, the primary tumour showed relatively little uptake and attention was.
called to the problem of comparing animal and human tumours, in particular
where the former become necrotic very much more rapidly than the latter. In
later qualitative studies on animal tumours, using fluorescence microscopy,
W\reissberg (1959) observed thatthefluorescence, andhence themepacrine, occurred
only irregularly or not at all in the tumour. Further, there was no evidence ofthe
fluorescence within the tumour cells.TUMOUR UPTAKE OF TRITIATED MEPACRINE
In some circumstances, however, mepacrine mayundergo considerable degrada-
tion in vivo. Thus after two weeks on a diet containing mepacrine, dogs showed
no evidence of further storage or greater elimination, yet only 4% of the daily
intake could be detected in the urine (Dearborn et al., 1943). Scudi and Jelinek
(1944) also observed the urinary excretion in dogsto be complex. Although the
problem of the metabolism of mepacrine has been examined by several groups
(Scudi and Jelinek, 1944; Hammick and Mason, 1945; King, Gilchrist and
Tarnoky, 1946), the metabolites are still largely unknown. Of those which have
been identified, two have lost the side-chain (Hammick and Mason, 1945). Thus
the observation, recently made by us, that mepacrine reacts under mild conditions
in vitro with thiols, leading to the separation of the mepacrine side-chain (Young
and Wild, unpublished; Young, 1963), may be relevant here. Full experimental
details and a discussion of this reaction will be presented elsewhere. With
simple thiols the products of the reaction are analogous to those found with
hydrogen sulphide (Asquith, Hammick and Williams, 1948), but in the case of
cysteine and glutathione this simple pattern is not followed, although the side-
*chain is still split off. Thus cysteine, incubated with mepacrine at 370 C. in
phosphate buffer, pH 7-1, for 48 hours, forms the insoluble N, S-bis(6-chloro-2-
methoxy-9-acridinyl)cysteine in about 50% yield. Although this reaction with
cysteine and glutathione has not been investigated in vivo, it is conceivable that
where concentrations of mepacrine are present for a length of time it may be
;significant. Thus some knowledge of the fate of the side-chain is important in
any consideration of the mepacrine as a carrier for the tritium. An alteration in
the nature ofthe molecule bearing the tritium is no disadvantage, ifthe new carrier
goes into, or remains in, the tumour. Whereas, in general, metabolites containing
the acridine nucleus will probably be fluorescent, the non-fluorescent side-chain
will not have been detected either by fluorescence microscopy or by the
methods used to estimate unchanged mepacrine. It should be noted however,
that the acridine derivatives formed by the reaction of mepacrine with cysteine
and glutathione are only very weakly fluorescent. We have therefore prepared
mepacrine labelled with high specific activity with tritium at C-1 in the side-
chain, and have examined the distribution of the tritium in rats bearing the
Walker 256 carcinoma. To provide the optimum therapeutic dose of radiation,
the localisation ofthe tritium within the tumour cells is necessary, since the mean
range ofthe tritium , particle in unit density tissue (1 u) is much smaller than the
diameter of most human cells. The uptake ofthe tritium by HeLa cells in tissue
culture and mouse Ehrlich ascites cells in vivo has therefore been examined by
autoradiography.
MATERIALS AND METHODS
Preparation of tritium labelled mepacrine dihydrochloride
This has been prepared in two stages from 1-diethylaminopentan-4-one using a
small scale adaptation of the method ofHaskelberg (1948) for the first stage, and
that of Magidson and Grigorowski (1936) for the second. The intermediate,
4-diethylamino-1-methylbutylamine, was not isolated.
A solution of1-diethylaminopentan-4-one (0.033 ml.) in anhydrous ammoniacal
ethanol (0.3 ml., 15 % w/v), containing Raney nickel as catalyst, was stirred in an
atmosphere of tritium gas (1 curie, i.e. 0 4 ml. at n.t.p.) in a microhydrogenation
apparatus similar to that of Glascock (1954). After 24 hours hydrogen gas was
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admitted and stirring continued until no further uptake occurred. The catalyst
was removed from the reaction mixture by centrifugation and the supernatant
concentrated in vacuo to small volume. To this solution 6,9-dichloro-2-methoxy-
acridine (0.035 g.) and phenol (c. 0-2 g.) were added and the stirred mixture heated
at 900 for 21 hours. Theresulting gold syrup waspartitioned between benzene and
20 % aqueous sodium hydroxide, and the benzene layer applied to an alumina
column. Elution with benzene led to the slow separation of several fluorescent
byproducts, the major of these being 6-chloro-2-methoxy-9-phenoxyacridine.
The mepacrine base remaining adsorbed on the column was eluted with benzene/
ether (1: 1) and converted into the hydrochloride using dry hydrogen chloride
gas. Yield 0-018 g. (20 % overall), m.p. 246-8°. A sample of normal mepacrine
hydrochloride had m.p. 248-50° and an identical u.v. spectrum (0.5 N hydro-
chloric acid). In two preparations the tritiated mepacrine dihydrochloride had a
specific activity of 1-2 curies/millimole (2-26 mc/mg.) and 1P6c/mM (3-2mo/mg.).
Paper chromatography (see under " position of the label ") showed one spot only
with which virtually all the radioactivity was associated. An 8 week old sample
had the same electrophoretic mobility (see under " Stability ") as a control of
normal mepacrine, and had 98-6 % of the radioactivity associated with it.
Position of the label
This has been confirmed by treatment ofthe tritiated mepacrine with hydrogen
sulphide, which leads to the removal of the side-chain (Asquith, Hammick and
Williams, 1948).
Through a solution of isotopically diluted (c. 1: 150) tritiated mepacrine
(5 mg.) in ethanol/" 880 " ammonia (4 ml., 1: 3), hydrogen sulphide was passed for
12 hours. The small amount of 6-chloro-2-methoxyacridan-9-thione which
separatedwas centrifuged off. Chromatograms (silicic acidimpregnatedWhatman
3 MM paper, n-butanol/acetic acid/water, 4: 1: 5) ofthe supernatant scanned for
(a) radioactivity (RF 0.23), (b) fluorescence and u.v. absorption (RF 0 94) and
(c) ninhydrin positive products (RF023), compared witha control of thetritiated
mepacrine (fluorescence and radio-activity, RF 0.64), demonstrated that more
than 99 % of the radio-activity resided with the side-chain.
Liability to exchange
Tritiated mepacrine, diluted with normal mepacrine (c. 1: 150), was dissolved
in distilled water and 6 % sulphuric acid. After 8 weeks at room temperature, the
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total activity of the solutions was compared with the activity which could be
extracted into benzene after the addition of alkali. The tritium label was thus
shown to be at least 94 % stable to proton exchange with the solvent water. This
figure may be low since (a) mepacrine base is strongly adsorbed on to glass surfaces
(Brodie and Udenfriend, 1943) and (b) slight hydrolysis of the mepacrine during
the 8 weeks may have produced water-soluble tritiated products.
Stability.-Electrophoresis (10% acetic acid, Whatman 3 MM paper) and
chromatography ofan 8week old sample ofthetritiatedmepacrinedihydrochloride,
which had been stored as the solid in the dark at - 250 C., showed the presence of
very small amounts of 6-chloro-2-methoxyacridone. This compound was not
present on chromatograms ofthe freshly prepared material, and further chromato-
grams showed that the amount present increased with time. As normal mepacrine
dihydrochloride is stable under these conditions, this decomposition is considered
to be due to self-irradiation.
Distribution of the tritium in tumour-bearing rats
Five rats bearing an 8 day old Walker 256 carcinoma were injected in the tail
vein with 05 ml. of a normal saline solution containing 2 mg. tritiated mepacrine
dihydrochloride (6-3 mc tritium). The animals were killed at intervals of 10
minutes, 1, 6, 24, and 48 hours, and the specimens stored at - 250 C. untilrequired
for counting. The tritium content of various tissues was determined using a
modification ofthe Schoniger (1955) oxygen flask combustion technique (Chipper-
field, 1962). Tissue samples of about 20 mg. wet weight are combusted in an
oxygen enriched atmosphere in the presence of normal non-active water. The
tritiated water vapour formed is absorbed in the large excess ofnormal water, and
can then be determined by liquid scintillation counting. The accuracy of this
method is about + 5 %.
Uptake of the tritium into tumour cells
HeLa cells in tissue culture were treated with a 2 x 10-5M solution oftritiated
mepacrine dihydrochloride for 24 and 48 hours. Smears were then examined by
autoradiography.
Mice with the Ehrlich ascites tumour were injected intraperitoneally with 1 mg.
tritiated mepacrine dihydrochloride (2-26 mc/mg.) and killed after 3, 7, 24 and 30
hours. A second group were treated with 2 mg. ofthe tritiated material and killed
at 0, 5, 24, 30 and 48 hours. Smears from the tumour were examined by fluores-
cence microscopy and autoradiography. Two further groups were treated as
above, but with normal commercial mepacrine, and the post-mortem specimens
examined for visible staining and fluorescence.
RESULTS
Distribution of tritium in rats bearing the Walker carcinoma
The specific activity of various tissues from the rats killed at intervals is set
out in Table I. Each figure is the average of the values obtained from 2-4
different samples of the same tissue. The agreement between these samples
varied markedly from tissue to tissue. Thus while the values for the liver were
within 7*5 % ofthe mean, those from the tumour consistently showed considerable
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TABLEI.-Activitims inTis8Ues of Rats Following a Single I.V. Injection of
TritiatedMepacrine
All values in muc/mg.
Each figure is the mean of 2-4 determinations on the same animal
10min. 1 hr. 6 hr. 24 hr. 48 hr.
Tumour . . . 17 . 15 . 18 . 13 . 5-8
Muscle . . . 13 . 34 . 19 . 10 . 4 4
Kidney . . . 150 . 138 . 117 . 50 . 34
Blood . . . . 5 0 . 1.9 . 1- 4 . 0 7t . 0.8
Bone marrow . . 34 . 87 . 145* . 81* . 108*
Brain. . . . 29 . 31 . 17 . 5-4 . 18
Testis . . . 3 5 . 50 . 4- 8 . 5-4 . 3 9
Liver. . . 36 . 64 . 115 . 105 . 60
Spleen . . . 42 . 68 . 64 . 82 . 39
Gut. . . 43 . 61 . 28 . 31 . 10
* One determination only.
tUnreliable value.
variation-individual valuesdiffering from each other by as much as a factor of
3.5. Of the other tissues only the determinations on the brain showed a con-
sistentlylargevariability, up to a factor of 2. This variability must be considered
to represent an uneven distribution of tritium in the organ. In the case of the
tumour this is not unduly surprising since the difficulty of the penetration ofdyes
into the tumour mass, with a consequently dye-poor area in the necrotic centre,.
has been demonstrated by Goldacre and Sylven (1962).
The amount of bone marrow extracted from three of the rats was sufficient for
only one determination in each case. The values obtained show a reasonable
consistency from rat to rat, and the large factor between the activity of the 48
hour bone-marrow specimen and the mean value for the tumour is far beyond
experimental error.
A conmparison of the rate ofuptake and initial loss of tritium from the tumour
and certain other tissues is shown in Fig. 1. The ratio
specific activity ofthe tissue
specific activity of the tumour
has been used to meet the problem of thevariability ofindividual animals in such
features as weight and possibly slightly different doses.
Uptake of the tritium into tumour cells
Autoradiographs ofmonolayer HeLa cells, treated with a 2 x10-5M solution
of tritiated mepacrine dihydrochloride for 24 and 48 hours, showed no evidence
ofanyuptake oftritium within the cells. A more concentrated solution ofnormal
mepacrine (4 X 10-4 M) produced a general toxic effect on the culture.
Autoradiographs ofair-dried smears ofEhrlich ascites tumour cells, taken from
mice treated (IP) with1 mg. and 2 mg. tritiated mepacrine and killed at various
intervals, showed no uptake of the tritium into the tumour cells at any time.
With the same doses ofnormalmepacrine no staining effects were observed. Mice
killed immediately after injection (IP) with 2 mg. tritiated or normal mepacrine
showed fluorescence only in the blood. In mice killed after 5 hours, about 2%/G
of the tumour cells appeared to fluoresce but no fluorescence was observed after
longer periods.
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DISCUSSION
It is clear from the activities of various tissues, set out in Table I, that at no
time is there an overall selective concentration of tritium in the tumour. After
both 24 and 48 hours, 5 out of the 9 tissues examined showed a higher tritium
concentration than that of the tumour. Most important from one hour onwards
the radiosensitive bone-marrow was much more active than the tumour. Not-
withstanding the reservations as to the accuracy of the measurements on the
bone-marrow, the factor of 20 after 48 hours is far beyond experimental error.
Further, no evidence was found for any uptake ofthe tritium label into HeLa cells
in tissue culture ormouseEhrlichascites tumour cellsinvivo. Hence theprospects
for tritiated mepacrine as a drug which is to provide selective irradiation of the
tumour, appear slight. The failure to observe any fluorescence within the ascites
cells after treatment with normal mepacrine, apart from a few cells after 5 hours,
confirms the observations of Weissberg (1959). Thus non-fluorescent radioactive
fragments, formed by metabolic degradation, are either produced in very small
amounts or, like the parent compound, are not taken up by the cells.
Quantitative values for the distribution ofnormal mepacrine in tumour-bearing
mice have been reported by Vassey and his co-workers (1955). The mepacrine
was administered over a period of time in the food, but nevertheless there is
general agreement with the results from the tritiated compound, the relative
concentrations ofmepacrine and tritium being liver > spleen > kidney > tumour
> testis > blood. The same pattern, excluding the tumour, has been observed
in healthy animals (Barlow, Auerbach and Rivenburg, 1945; Snow and Hurst,
1956). Thus although under certain circumstances considerable degradation of
mepacrine may occur in vivo (Dearborn et al., 1943; Scudi and Jelinek, 1944), anyJ. M. YOUNG, F. WILD AND I. SIMON-REUSS
radioactive fragments derived from a single small dose oftriated mepacrine do not
in general lead to a distribution of tritium significantly different from that of the
parent compound. There are two tissues which are possibly interesting exceptions
to this generalisation.
(a) The concentration of normal mepacrine in the bone-marrow has been little
studied. However, for dogs on a daily dosage it was comparable with that inthe
kidney and slightly less than that in the spleen (Dearborn et al., 1943) and thus
comparatively less than the amount oftritium found in the present experiments.
(b) The mepacrine content of the brain in tumour-bearing mice (Vassey et al.,
1955), healthy rats (Snow and Hurst, 1956) and rabbits (Brilmayer et al., 1955)
was very small. The relatively large amounts of tritium found in the brain up to
6 hours could therefore indicate the presence of the side-chain unattached to the
acridine nucleus. This is of interest since mepacrine has been used in the treat-
ment of petit mal (Sibley, 1962) and is known to give rise to occasional toxic
psychoses (Goodman and Gilman, 1955). Moreover the -CH2.CH2.NR2 residue
isfrequently found in psychomimetic and psychotherapeutic substances (Downing,
1962; Jucker, 1963).
Studies on rats bearing the Walker 256 carcinoma, which had been given a
single subcutaneous injection of 5 mg. of normal mepacrine, were carried out by
Brilmayer and his co-workers (1955). They reported that after 24 hours the
kidney, liver and spleen showed high concentrations ofmepacrine, but these levels
decreased more rapidly than that of the tumour. A selective concentration was
apparent in the tumour after 48 hours. However we have not observed this
effect in the experiments with tritiated mepacrine. The variation of the ratio
specific activity in tissue
specific activity in tumour
with time for the liver, kidney, muscle and bone-marrow is shown in Fig. 1. In
particular the amount of tritium in the liver relative to the tumour rises steadily
with time. Examination ofthe mean values ofthe activity in the tumour suggests
that between 10 minutes and 24 hours its tritium content is essentially constant.
It is thus reasonable to suppose that the observations of Goldacre and Sylven
(1962) on the very slow diffusion of various dyes into tumours after saturating
a narrow outer zone, are also applicable to mepacrine. Gellhorn et al. (1961)
have also noted the difficulty ofintroducing large doses ofmepacrine into tumours.
With the tritiated compound, where we are not so much interested in the anti-
tumour activity of mepacrine per se as in the introduction of tritium into the
tumour, concentrations of mepacrine relatively smaller than those required by
Gellhorn might have sufficed. However following the failure to observe tritium
within tumour cells, the relatively much larger amounts found in other organs,
particularly in the radiosensitive bone-marrow, make the possible clinical use of
tritiated mepacrine very doubtful.
SUMMARY
The feasibility of providing a highly localised source of radiation within a
tumour, by means of an organic compound containing tritium, depends on having
a carrier molecule which is to a certain degree selectively absorbed by the malig-
nant tissue. The suitability of mepacrine for this purpose has been examined.
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Since the metabolism of the parent compound may lead to non-fluorescent side-
chain fragments, which might be taken up by the tumour cells, the tritium label
has been introduced atC-1 inthe side-chain. Determinationofthe tritium content
ofvarious organs from rats bearing the Walker 256 carcinoma at different intervals
after a single intravenous injection of2 mg. (6.3 mc) oftritiated mepacrine, showed
that there was no overall concentration of tritium in the tumour. Autoradio-
graphy of HeLa cells from tissue culture and mouse Ehrlich ascites tumour cells
treated with tritiated mepacrine demonstrated that the tritium was not taken up
by the malignant cells. Further studies using fluorescence microscopy on Ehrlich
ascites cells treated both with normal and tritiated mepacrine gave similar results.
The pattern of the gross distribution of the tritium in various organs showed a
general agreement with that reported in the literature for mepacrine itself.
Relatively larger amounts of tritium were found in the bone marrow and in the
brain. The possible presence of the free dialkylamino-alkylamino side-chain in
the brain is ofinterest in connection with the psychomimetic effects ofmepacrine.
A report that rats with the Walker 256 carcinoma showed an effective selective
concentration ofmepacrine after 48 hours has not been confirmed. The maximal
amount oftritium is taken up by the tumourwithin 10 minutes ofinjection and the
content then remains effectively constant over the next 24 hours. In the period
studied the amount oftritium in the liver, relative to that in the tumour, increased
with time.
Since this manuscript was originally prepared, Ackerman and Shemesh (1964)
have reported that certain lung tumours, as opposed to subcutaneous, intra-
peritoneal and intrahepatic tumours in rats, fluoresced strongly after treatment
with mepacrine. Studies with L31I labelled mepacrine showed marked radio-
activity in the malignant areas as compared with apparently normal lung.
Evaluation of the therapeutic possibilities of this interesting observation must
await further data. However, in spite ofthe negative results to the present with
tritiated mepacrine, it would seem that it may have potential in the field of lung
tumours.
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